MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
MiNK Therapeutics, Inc. (INKT)
Company Research
Source: GlobeNewswire
NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 11-15, 2026, in Boston, MA. Presentation Details: Abstract Title: AgenT-797 Allogeneic iNKT Cell Therapy Demonstrates Adaptive Immune Modulation in Cancer and ARDSPresenter: Terese C. Hammond, MD; Program Director of Pulmonary and Critical Care, Kaweah Health Medical Center; Head of Inflammatory and Pulmonary Diseases, MiNK Therapeutics Additional information on the poster presentation including session location and timing details will be made available by ASGCT via the ASGCT Annual Meeting con
Show less
Read more
Impact Snapshot
Event Time:
INKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INKT alerts
High impacting MiNK Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
INKT
News
- MiNK Therapeutics (INKT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $35.00 price target on the stock.MarketBeat
- MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference [TheStreet.com]TheStreet.com
- MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference [Yahoo! Finance]Yahoo! Finance
- MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International ConferenceGlobeNewswire
- MiNK Therapeutics Inc (INKT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ... [Yahoo! Finance]Yahoo! Finance
INKT
Earnings
- 3/31/26 - Beat
INKT
Analyst Actions
- 4/1/26 - HC Wainwright
INKT
Sec Filings
- 3/31/26 - Form 10-K
- 3/31/26 - Form 8-K
- 3/27/26 - Form 8-K
- INKT's page on the SEC website